Home > Resources > Company Profiles > Helicos BioSciences Corporation

Helicos BioSciences Corporation (HLCS)

PRINT
SHARE
TEXT SIZE:
Send a copy to me

Separate multiple email addresses (max 20) with commas.

0/1500
Letters are not case-sensitive, disregard spaces.
captcha image
Try a New One
This helps us prevent automated registrations and spamming.
Stanley N. Lapidus , CEO/Director/Founder/Chairman of the Board
Industry: Healthcare
OPEN
LAST
$
PREV CLOSE
CHANGE
VOLUME


Overview
News
People
Financials

Company Information

Stanley N. Lapidus, CEO/Director/Founder/Chairman of the Board

One Kendall Square

Building 700

Cambridge, MA 02139

US Map it

Phone: (617) 264-1800

Fax:

www.helicosbio.com



Overview

A life sciences company, which focuses on innovative genetic analysis technologies for the research, drug discovery and clinical diagnostics markets.

Employees

Number of Employees: 114
Revenue per Employee: $6,557

Top Executives

Kevin G. Lafond, CPA, Controller/Treasurer
Dr. J. William Efcavitch, PhD, Senior VP, Divisional
Stephen J. Lombardi, COO/President

Stephen P. Hall, Senior VP/CFO/Treasurer/Chief Accounting Officer

Board of Directors

Kevin G. Lafond, CPA, Controller/Treasurer
Ronald A. Lowy, Director
Theo Melas-Kyriazi, Director

Robert F. Higgins, Director
Dr. Peter Barrett, Ph.D., Director
Stephen P. Hall, Senior VP/CFO/Treasurer/Chief Accounting Officer

Financials

Quarterly
Annual

Income Statement 06/2008 03/2008 11/2007 08/2007
Sales -491 K. -357 K. -372 K. -382 K.
Gross Operating Profit 604 K. 474 K. 602 K. 525 K.
Operating Income before D & A (EBITDA) -11.28 Mil. -10.5 Mil. -10.26 Mil. -8.08 Mil.
Total Income Before Interest Expenses (EBIT) -11.44 Mil. -10.32 Mil. -9.89 Mil. -8.04 Mil.
Total Net Income -11.8 Mil. -10.42 Mil. -9.96 Mil. -8.07 Mil.
Basic EPS, Total -0.57 0.03 -0.48 -0.87
Diluted EPS, Total -0.57 0.03 -0.48 -0.87

BALANCE STATEMENT 06/2008 03/2008 11/2007 08/2007
Cash and Equivalents 37.92 Mil. 52.68 Mil. 54.86 Mil. 64.28 Mil.
Total Assets 44.42 Mil. 55.36 Mil. 55.61 Mil. 64.96 Mil.
Total Liabilities 6.62 Mil. 4.67 Mil. 4.81 Mil. 4.51 Mil.
Total Capitalization 42.55 Mil. 54.22 Mil. 53.93 Mil. 63.33 Mil.

Cash Flow 06/2008 03/2008 11/2007 08/2007
Net Cash From Continuing Operations -13.01 Mil. -32.8 Mil. -21.94 Mil. -13.41 Mil.
Net Cash From Investing Activities -1.49 Mil. -1.39 Mil. -554 K. 30 K.
Net Cash From Financing Activities -268 K. 76.28 Mil. 66.76 Mil. 67.07 Mil.
Net Change in Cash & Cash Equivalents -14.77 Mil. 42.09 Mil. 44.27 Mil. 53.69 Mil.

powered by Interactive Data

Income Statement 2008 2007
Sales -1.44 Mil. -883 K.
Gross Operating Profit 2.02 Mil. 1.04 Mil.
Operating Income before D & A (EBITDA) -37.05 Mil. -20.26 Mil.
Total Income Before Interest Expenses (EBIT) -36.53 Mil. -20.37 Mil.
Total Net Income -36.8 Mil. -20.58 Mil.
Basic EPS, Total -4.23 -16.35
Diluted EPS, Total -4.23 -16.35

BALANCE STATEMENT 2008 2007
Cash and Equivalents 52.68 Mil. 10.59 Mil.
Total Assets 55.36 Mil. 12.04 Mil.
Total Liabilities 4.67 Mil. 3.38 Mil.
Total Capitalization 54.22 Mil. -35.5 Mil.

Cash Flow 2008 2007
Net Cash From Continuing Operations -32.8 Mil. -16.53 Mil.
Net Cash From Investing Activities -1.39 Mil. -4 Mil.
Net Cash From Financing Activities 76.28 Mil. 22.55 Mil.
Net Change in Cash & Cash Equivalents 42.09 Mil. 2.02 Mil.

powered by Interactive Data





Related Companies by Market Cap
Company Name
Price
Change
Market Cap
Hi-Tech Pharmacal Co., Inc.
121.8 Mil.
SeraCare Life Sciences, Incorporated
94.3 Mil.
Caraco Pharmaceutical Laboratories
481.63 Mil.
RXElite, Incorporated
41.46 Mil.

Company Profile Change Request

The data provided in our company profiles comes from third party information providers.

  • If you have a change request regarding a publicly traded company, click here
  • If your request pertains to a private company, click here
Also in Portfolio.com
Most Emailed
Recently Commented